

Servier and Gustave Roussy sign a framework agreement for a strategic collaboration in oncology and immuno-oncology

A long-term strategic collaboration on an R&D program in adult and pediatric oncology

Paris, France, December 14, 2022 – Servier, a global pharmaceutical group, and Gustave Roussy, a leading cancer treatment center in Europe, announce the signing of a framework agreement relating to collaborative projects in oncology and immuno-oncology.

This renewable four-year agreement formalizes a strategy of a long-term collaboration between Servier and Gustave Roussy, who share the common goal of cancer research and treatment. It is the reference framework for the co-development of fundamental and translational research for the benefit of cancer patients. The agreement also includes early phase clinical trials with innovative molecules from Servier's oncology pipeline to be conducted by Gustave Roussy.

At this time, five research and development projects in adult and pediatric oncology will be launched. They concern indications of interest developed by Servier and, in particular, certain indications that Gustave Roussy consider to be still associated with unmet needs. These projects concern both the development of new preclinical models and the identification of predictive biomarkers to optimize therapeutic management.

Claude Bertrand, Executive Vice-President R&D of Servier, states: “We are delighted with the signing of this framework agreement, which is a continuation of the constructive collaboration initiated several years ago with Gustave Roussy, recognized for its substantial expertise and advanced research capacities in oncology. This agreement illustrates Servier's commitment to oncology and its strong collaborative innovation dynamics to accelerate the discovery of innovative therapeutic solutions for patients. The opening of the Servier R&D institute within the Paris-Saclay global innovation hub in the first half of 2023 will provide a new dimension to this strategic partnership. “

Prof. Fabrice Barlesi, CEO of Gustave Roussy, adds: "The framework agreement we are signing today with Servier is strategic for patients living with cancer. It is the culmination of a long-standing collaboration that will eventually be reflected in the Paris-Saclay Cancer Cluster. The first research projects in hematology, immuno-oncology and pediatrics illustrate the scope and momentum that this agreement will further boost our collaboration."

Prof. Angelo Paci, Program Leader Oncology and Immuno-onco at Servier, emphasizes: “This collaboration allows combining the expertise of Servier and Gustave Roussy, with the common objective of initiating ambitious R&D projects for purposes of developing therapeutic innovations targeting resistant cancers, such as certain acute myeloid leukemias in adults, and treatments targeting cancers with high unmet needs, such as certain brain tumors in children.”

Servier press contact

Sonia Marques: presse@servier.com | Tel. +33 (0)1 55 72 40 21

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,800 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.7 billion in 2021.

More information on the new Group website: servier.com

Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)

Gustave Roussy press contacts

Claire Parisel - Raphaëlle Bartet: presse@gustaveroussy.fr | Tel. +33(0)1 42 11 50 59 – +33 (0)6 17 66 00 26

About Gustave Roussy

Ranked as the leading European Cancer Centre and third in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient's human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient's life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: a quarter of patients treated are included in clinical trials.

For further information: www.gustaveroussy.fr/en, [Twitter](#), [Facebook](#), [LinkedIn](#), [Instagram](#)